The B side of B cells in NAFLD
Fanta Barrow, Xavier S. Revelo – 26 March 2022
ATP7B gene therapy of autologous reprogrammed hepatocytes alleviates copper accumulation in a mouse model of Wilson’s disease
Hongxia Cai, Xing Cheng, Xiao‐Ping Wang – 26 March 2022
Alpha‐1‐Antitrypsin Deficiency
Anandini Suri, Dhiren Patel, Jeffery Teckman – 26 March 2022
Cellular heterogeneity and transcriptomic profiles during intrahepatic cholangiocarcinoma initiation and progression
Tingjie Wang, Chuanrui Xu, Zhijing Zhang, Hua Wu, Xiujuan Li, Yu Zhang, Nan Deng, Ningxin Dang, Guangbo Tang, Xiaofei Yang, Bingyin Shi, Zihang Li, Lei Li, Kai Ye – 26 March 2022
Alpha‐1‐Antitrypsin Deficiency
Anandini Suri, Dhiren Patel, Jeffery Teckman – 26 March 2022
IL‐1 receptor antagonist plus pentoxifylline and zinc for severe alcohol‐associated hepatitis
Gyongyi Szabo, Mack Mitchell, Craig J. McClain, Srinivasan Dasarathy, Bruce Barton, Arthur J. McCullough, Laura E. Nagy, Aimee Kroll‐Desrosiers, David Tornai, Hyesung Alice Min, Svetlana Radaeva, M. E. Blair Holbein, Lisa Casey, Jennifer Cuthbert – 26 March 2022
Letter to the editor: Non‐invasive diagnosis of porto‐sinusoidal vascular disease
Ankur Jindal – 26 March 2022
Efficient silencing of hepatitis B virus S gene through CRISPR‐mediated base editing
- Read more about Efficient silencing of hepatitis B virus S gene through CRISPR‐mediated base editing
Hao Zhou, Xiaomei Wang, Clifford J. Steer, Guisheng Song, Junqi Niu – 25 March 2022 – Hepatitis B virus (HBV) infection is a major risk factor of liver cirrhosis and hepatocellular carcinoma. Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR‐associated protein 9 (Cas9) has been used to precisely edit the HBV genome and eliminate HBV through non‐homologous end‐joining repair of double‐stranded break (DSB). However, the CRISPR/Cas9‐mediated DSB triggers instability of host genome and exhibits low efficiency to edit genome, limiting its application.
Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score
Rish K. Pai, Vipul Jairath, Malcolm Hogan, Guangyong Zou, Oyedele A. Adeyi, Quentin M. Anstee, Bashar A. Aqel, Cynthia Behling, Elizabeth J. Carey, Andrew D. Clouston, Kathleen Corey, Brian G. Feagan, David E. Kleiner, Christopher Ma, Stefanie C. McFarlane, Mazen Noureddin, Vlad Ratziu, Mark A. Valasek, Zobair M. Younossi, Stephen A. Harrison, Rohit Loomba – 24 March 2022
Cirrhotic cardiomyopathy: Appraisal of the original and revised criteria in predicting posttransplant cardiac outcomes
Ashley Spann, Christopher Coe, Teminioluwa Ajayi, Garren Montgomery, Mohammed Shwetar, Adesola Oje, Jeffrey Annis, James C. Slaughter, Sophoclis Alexopoulos, Evan Brittain, Manhal Izzy – 24 March 2022 – Cardiovascular disease (CVD) significantly contributes to morbidity and mortality after liver transplantation (LT). Cirrhotic cardiomyopathy (CCM) is a risk factor for CVD after transplant. CCM criteria were originally introduced in 2005 with a revision proposed in 2020 reflecting echocardiographic technology advancements.